The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
暂无分享,去创建一个
Stanley B. Cohen | P. Geusens | W. Lems | K. Saag | N. Lane | J. Adachi | R. Dore | Li Chen | Shuang Huang | R. Stad | M. Mcdermott | S. Cohen | M. McDermott
[1] R. Eastell,et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. , 2020, The Journal of clinical endocrinology and metabolism.
[2] B. Langdahl,et al. Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial , 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] F. Wolfe,et al. Medications associated with fracture risk in patients with rheumatoid arthritis , 2019, Annals of the rheumatic diseases.
[4] Ji-Min Kim,et al. Prevalence and Fracture Risk of Osteoporosis in Patients with Rheumatoid Arthritis: A Multicenter Comparative Study of the FRAX and WHO Criteria , 2018, Journal of clinical medicine.
[5] Jacques P. Brown,et al. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double‐Blind, Phase 2, Parallel Group Study , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] P. Geusens,et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. , 2018, The lancet. Diabetes & endocrinology.
[7] I. Reid,et al. Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates , 2018, Calcified Tissue International.
[8] Jacques P. Brown,et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo‐Controlled FREEDOM Trial and Its Extension , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[9] Haifeng Guo,et al. Bone fracture risk in patients with rheumatoid arthritis , 2017, Medicine.
[10] Raveendhara R. Bannuru,et al. American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 2017 .
[11] D. Aeberli,et al. Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures , 2017, Osteoporosis International.
[12] Hang Lee,et al. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up). , 2017, Bone.
[13] Y. Fujiwara,et al. Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice. , 2016, American journal of physiology. Endocrinology and metabolism.
[14] K. Saag,et al. Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis , 2016, Osteoporosis International.
[15] N. Freemantle,et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women , 2011, Osteoporosis International.
[16] J. S. San Martin,et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. , 2011, The Journal of clinical endocrinology and metabolism.
[17] R. Rizzoli,et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three‐year continued therapy and resolution of effect , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[18] Stanley B. Cohen,et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates , 2009, Annals of the rheumatic diseases.
[19] B. Bresnihan,et al. Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade , 2010, Rheumatology International.
[20] Claus Christiansen,et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.
[21] J. S. San Martin,et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. , 2008, Bone.
[22] Sundeep Khosla,et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. , 2008, Endocrine reviews.
[23] R. Kitazawa,et al. Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels , 2008, Journal of cellular biochemistry.
[24] Steven W. Martin,et al. A Single‐Dose Placebo‐Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[25] A. Bertolotto,et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. , 2004, The Journal of clinical endocrinology and metabolism.
[26] Stanley B. Cohen,et al. Oral glucocorticoid use is associated with an increased risk of fracture , 2004, Osteoporosis International.
[27] H. Frost. Bone's mechanostat: a 2003 update. , 2003, The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology.
[28] W. Kratzer,et al. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease , 2003, European journal of gastroenterology & hepatology.
[29] P. Tak,et al. Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis , 2002, Annals of the rheumatic diseases.
[30] A. Algra,et al. Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. , 2001, Rheumatology.
[31] D. Lacey,et al. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells , 1999 .
[32] D. Lacey,et al. Printed in U.S.A. Copyright © 1999 by The Endocrine Society Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in , 2022 .